Foundayo (Orforglipron) GLP-1 pill: Everything you need to know

Weight-loss treatments in the UK are changing quickly. Until recently, most of the best-known GLP-1 weight-loss medicines, including Mounjaro and injectable Wegovy, involved a weekly injection. Now, another option is joining the growing range of weight-loss tablets.

On August 10, 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Orforglipron, sold under the brand name Foundayo, for weight management and type 2 diabetes. This made the UK the first country in Europe to authorise the medicine.

Foundayo is a once-daily GLP-1 tablet developed by Eli Lilly, the pharmaceutical company behind Mounjaro. Unlike some other oral GLP-1 medicines, there is no requirement to take it on an empty stomach or wait before eating or drinking.

So, how does it work, how much weight could you lose, who could be eligible, and when will you actually be able to get it in the UK? Here is what we know so far.

Orforglipron is the active ingredient in Foundayo, a prescription-only medicine developed for weight management and type 2 diabetes. It belongs to a group of medicines called GLP-1 receptor agonists. This is the same general family of medicines as semaglutide, the active ingredient in Wegovy, although orforglipron is chemically quite different.

Most established GLP-1 medicines are peptide-based drugs. Orforglipron, instead, is what is known as a small-molecule, non-peptide GLP-1 receptor agonist. One of the practical advantages of this design is that the medicine can be absorbed when taken as an ordinary tablet without the strict eating and drinking routine required by some other oral GLP-1 medicines.

GLP-1 is a hormone naturally released by your body after you eat. Among other things, it helps regulate appetite and signals to your brain that you have eaten enough.

Orforglipron activates GLP-1 receptors and strengthens these signals. According to the MHRA, it acts on areas of the brain involved in appetite regulation, helping people feel fuller for longer while reducing hunger and food cravings. This can make it easier to eat smaller portions and maintain a reduced-calorie diet over time.

Foundayo is not intended to replace changes to your diet or activity levels. Its UK authorisation is specifically for use alongside a reduced-calorie diet and increased physical activity.

Orforglipron can also help lower elevated blood glucose in people with type 2 diabetes, which is why the MHRA has authorised it for both weight management and improving glycaemic control in inadequately controlled type 2 diabetes.

The main Phase 3 weight-loss study behind orforglipron is called ATTAIN-1. It included 3,127 adults with obesity, or overweight accompanied by at least one weight-related health condition, who did not have diabetes. Participants received orforglipron or a placebo alongside diet and physical activity support for 72 weeks.

The strongest results were seen at the highest studied dose. People who remained on treatment lost an average of 12.4% of their starting body weight after 72 weeks, compared with 0.9% for people receiving placebo. When researchers included participants regardless of whether they completed treatment, average weight loss was 11.1%, compared with 2.1% for placebo. Among people remaining on treatment at the highest dose, around 60% lost at least 10% of their starting weight and around 40% lost 15% or more.

It should be noted that these are averages rather than guarantees. Some people will lose considerably more or less weight, and results depend on factors including dose, how long treatment continues, side effects, diet, and physical activity.

This is where Foundayo could prove particularly convenient, because the tablet is taken once per day and, according to the MHRA, can be taken at any time of day without food or water restrictions.

That makes it noticeably different from the oral form of Wegovy. Oral semaglutide has specific instructions around taking the tablet on an empty stomach, using only a small amount of water and waiting before eating, drinking, or taking other medicines. Foundayo doesn’t require this routine.

However, treatment doesn’t start at the highest dose straight away. The MHRA-approved dosing schedule begins at 0.8 mg and can then progress through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg. Patients should spend at least one month at each dose level before moving up.

Gradually increasing a GLP-1 dose gives your body time to adjust to the medicine and can help manage gastrointestinal side effects. Your prescriber will tell you which dose to take and when, and you should not increase your dose faster than advised.

Both Foundayo and the Wegovy pill are once-daily GLP-1 medicines approved for weight management in the UK, but they contain completely different active ingredients.

Foundayo contains orforglipron and is manufactured by Eli Lilly. Meanwhile, the Wegovy pill contains semaglutide and is manufactured by Novo Nordisk. The MHRA authorised the Wegovy tablet in June 2026, followed by Foundayo in August 2026.

The biggest day-to-day difference is how they are taken. Foundayo can be taken at any time, with or without food and without a specific amount of water. The Wegovy tablet has stricter administration requirements and needs to be taken on an empty stomach, followed by a waiting period before food, drink, or other medicines.

For someone who finds complicated morning medication routines difficult to follow, that flexibility could make Foundayo easier to fit into their everyday schedule. However, convenience alone doesn’t make one medicine medically “better” than another. Your medical history, weight, existing medicines, previous treatments, side effects, and personal circumstances all need to be considered by your GP or prescriber when choosing a weight-management medicine, as people respond to weight loss medications differently, so there is no one-size-fits-all approach.

Foundayo and the Wegovy pill stand apart because they are the UK's oral GLP-1 weight-loss treatments. There is, however, an important practical difference between them, as explained above.

The older oral treatments work differently altogether. Mysimba contains naltrexone and bupropion and follows a four-week dose-escalation schedule, reaching a maximum of two tablets twice daily. Although it is licensed for weight management in eligible adults, NICE does not currently recommend it for routine NHS treatment of obesity.

Orlistat does not act on appetite at all. Instead, it inhibits enzymes involved in digesting dietary fat, meaning some of the fat you eat is not absorbed. Prescription-strength Xenical is normally taken with main meals, while the lower-dose Alli formulation can be supplied without a prescription under pharmacist supervision.

It‘s difficult to say that one weight-loss pill is simply “better” than another. They work differently, have different eligibility criteria and side-effect profiles, and may suit different people. A pharmacist or prescriber can assess your medical history, current medicines and weight-management goals before recommending an appropriate treatment.

The MHRA has authorised Foundayo for weight loss and long-term weight management in adults who have either a BMI of 30 or above, or a BMI between 27 and 30 together with at least one weight-related health condition. Meeting the BMI criteria, however, doesn’t automatically mean Foundayo will be suitable for you.

It’s a prescription-only medicine, so a pharmacist will need to review your medical history, current medication and other relevant health information before deciding whether treatment is appropriate.

An exact UK private prescription price has not yet been announced. Eli Lilly told Reuters that Foundayo will have a lower private UK list price than Mounjaro, which has a list price of £330 for a month's supply, but the company has not yet disclosed Foundayo's actual UK figure. Below we've captured a price matrix of all the weight loss pills so far:

As with other GLP-1 medicines, digestive symptoms are the most commonly reported side effects. The MHRA currently lists the most common side effects of Orforglipron as:

• nausea
• constipation
• diarrhoea
• vomiting
• indigestion
• abdominal pain

Clinical trials found that the overall safety profile was broadly consistent with the GLP-1 medicine class, with gastrointestinal problems accounting for many of the reported side effects.

Because Foundayo has only just received UK authorisation, patients should follow the UK Patient Information Leaflet supplied with the medicine once it becomes available and speak to their prescriber or pharmacist about side effects that are severe or persistent.

Foundayo is already approved in the UK, but approval and availability are not quite the same thing. The MHRA authorised the medicine on August 10, 2026. Eli Lilly has subsequently said that it expects Foundayo to launch in the UK later in August through private prescription services.

That means private patients could potentially have access very soon, subject to stock reaching pharmacies and individual prescribing services being ready to offer it. As with any prescription weight-loss medicine, you will still need an assessment by an appropriate prescriber before Foundayo can be supplied.

Will Orforglipron be available on the NHS?

Not yet.

The MHRA has specifically confirmed that Foundayo is not currently available through the NHS. Regulatory approval determines whether a medicine can legally be prescribed in the UK, but it doesn’t automatically mean that the NHS will fund it.

The National Institute for Health and Care Excellence (NICE) is currently assessing orforglipron for managing obesity. Its appraisal is in development, with publication currently expected on November 18, 2026. Until that process is complete, private prescription services are expected to provide the first route to treatment.